Live Yum Brands Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Autonomix Medical, Inc.

Get SEC filing alerts via email and in your feed for Autonomix Medical, Inc.

AMIX

Autonomix Medical, Inc.

About Autonomix Medical, Inc.

Autonomix Medical, Inc. develops advanced catheter-based medical devices for sensing and treating peripheral nervous system disorders. Its proprietary microchip-enabled sensing array detects low-voltage neural signals with high precision, enabling targeted radiofrequency ablation therapies. Initially focused on managing pancreatic cancer pain, the technology platform aims to address broader indications including chronic pain, hypertension, and other nerve-related conditions. The company’s business model centers on disposable catheters and software solutions for hospital catheter labs.
This description was generated via AI from an annual report. Updated 10 months ago.

Latest SEC Filings from Autonomix Medical, Inc.

1
1
Autonomix Medical, Inc. Autonomix Medical Reports $16.7 Million Net Loss and Financial Challenges in Latest 10-K Filing

Via official filing (AI summary) | about 2 months ago | 0 comments

2
1
Autonomix Medical, Inc. Autonomix Medical Reports Increased Losses and Need for Additional Capital

Via official filing (AI summary) | 5 months ago | 0 comments

3
1
Autonomix Medical, Inc. Autonomix Medical Reports Increased Net Losses and Rising Operating Expenses for Six Months Ended September 30, 2025

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
Autonomix Medical, Inc. Autonomix Medical Reports $3.3 Million Net Loss and Increased Operating Expenses for Q2 2025

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
Autonomix Medical, Inc. Autonomix Medical Reports Financials and Progress in Clinical Trials for Fiscal Year Ending March 31, 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Autonomix Medical, Inc. Autonomix Medical Reports Decreased Net Loss and Increased R&D Expenses for Quarter Ended December 31, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Autonomix Medical, Inc. Autonomix Medical Reports Financial Results, Completes Reverse Stock Split, and Enters License Agreement

Via official filing (AI summary) | over 1 year ago | 0 comments